France's Sanofi raises earnings forecast, pleased with eczema drug uptakeFrance’s Sanofi (SASY.PA) raised its 2017 earnings forecast, citing strong second-quarter growth in consumer healthcare, vaccines and its Genzyme unit and said it was encouraged by U.S. uptake of eczema drug Dupixent. Sanofi’s EPS in 2016 stood at 5.68 euros ($6.66). In March, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ (REGN.O) and Sanofi’s biologic drug for atopic dermatitis – also referred to as eczema – Dupixent, that will sell for a list price of $37,000 for a year of treatment.


Read More At Article Source | Article Attribution